tiletamine hydrochloride has been researched along with DDD MPGNII in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asano, T; Horiguchi, Y; Kikuchi, E; Kosaka, T; Miyajima, A; Nakashima, J; Ohigashi, T; Oya, M; Umezawa, K | 1 |
1 other study(ies) available for tiletamine hydrochloride and DDD MPGNII
| Article | Year |
|---|---|
The novel NF-kappaB activation inhibitor dehydroxymethyl-epoxyquinomicin suppresses anti-Thy1.1-induced glomerulonephritis in rats.
Topics: Animals; Antibodies; Benzamides; Cell Proliferation; Cyclohexanones; Glomerulonephritis, Membranoproliferative; Kidney Glomerulus; NF-kappa B; Rats; Thy-1 Antigens | 2008 |